Yichuan Xia

1.2k total citations · 1 hit paper
6 papers, 892 citations indexed

About

Yichuan Xia is a scholar working on Pulmonary and Respiratory Medicine, Dermatology and Oncology. According to data from OpenAlex, Yichuan Xia has authored 6 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 2 papers in Dermatology and 2 papers in Oncology. Recurrent topics in Yichuan Xia's work include Dermatology and Skin Diseases (2 papers), Asthma and respiratory diseases (2 papers) and Lung Cancer Treatments and Mutations (2 papers). Yichuan Xia is often cited by papers focused on Dermatology and Skin Diseases (2 papers), Asthma and respiratory diseases (2 papers) and Lung Cancer Treatments and Mutations (2 papers). Yichuan Xia collaborates with scholars based in United States, United Kingdom and Belgium. Yichuan Xia's co-authors include C.E.M. Griffiths, Bruce Strober, Vincent Ho, Peter van de Kerkhof, Neil Goldstein, Newman Yeilding, Lisa T. Dooley, Alan Menter, B. Zhou and Cynthia Guzzo and has published in prestigious journals such as New England Journal of Medicine, Journal of Pharmacology and Experimental Therapeutics and Lung Cancer.

In The Last Decade

Yichuan Xia

5 papers receiving 867 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

2010 644 citations C.E.M. Griffiths, Bruce Strober et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Yichuan Xia

Since Specialization

Citations

This map shows the geographic impact of Yichuan Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yichuan Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yichuan Xia more than expected).

Fields of papers citing papers by Yichuan Xia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yichuan Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yichuan Xia. The network helps show where Yichuan Xia may publish in the future.

Co-authorship network of co-authors of Yichuan Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Yichuan Xia. A scholar is included among the top collaborators of Yichuan Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yichuan Xia. Yichuan Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast 2025 ·Oncology and Therapy ·Balázs Halmos, (unknown), (unknown), Wade T. Iams, Xiuning Le, (unknown), (unknown), Luis E. Raez, Jonathan W. Riess, Joshua K. Sabari, (unknown), (unknown), Yichuan Xia, (unknown), Denise D’Andrea, (unknown), Andrew L. Johnson, Melissa L. Johnson	0
2	Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer 2025 ·Lung Cancer ·Natasha B. Leighl, José Trigo, Keunchil Park, Se‐Hoon Lee, Nicolas Girard, Santiago Viteri, Pilar Garrido, Matthew Krebs, Meena Thayu, Roland E. Knoblauch, John Xie, Joshua Bauml, Robert W. Schnepp, Anil Londhe, Yichuan Xia, Parthiv J. Mahadevia, Byoung Chul Cho	1
3	Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes 2020 ·New England Journal of Medicine ·Teresa Quattrin, Michael J. Haller, Andrea K. Steck, Eric I. Felner, Yinglei Li, Yichuan Xia, Jocelyn H. Leu, (unknown), Joseph A. Hedrick, Mark Rigby, Frank Vercruysse	162
4	A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma 2018 ·Annals of Allergy Asthma & Immunology ·Alexa P. Kollmeier, Elliot S. Barnathan, Christopher O’Brien, Bin Chen, Yichuan Xia, Bei Zhou, Matthew J. Loza, Philip E. Silkoff, (unknown), Robin L. Thurmond	16
5	The Histamine H4 Receptor Antagonist, JNJ 39758979, Is Effective in Reducing Histamine-Induced Pruritus in a Randomized Clinical Study in Healthy Subjects 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Alexa P. Kollmeier, (unknown), Bin Chen, Paul J. Dunford, Andrew Greenspan, Yichuan Xia, Xie L. Xu, Bei Zhou, Robin L. Thurmond	69
6	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis breakdown → 2010 ·New England Journal of Medicine ·C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, (unknown), Newman Yeilding, Cynthia Guzzo, Yichuan Xia, B. Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter	644

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact